Zyprexa news | Breaking Zyprexa news | Zyprexa

Lilly profit beats forecasts, helped by lower tax

...The drug's sales fell 15 percent in the United States, but grew 6 percent in overseas markets.Sales of Strattera, Lilly's treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase the risk of suicidal thoughts among children and adolescents.Sales of Lilly's diabetes products rose 11 percent to $750 million, helped by the launch of Byetta and higher prices for older treatments.Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.Sales of Cialis, the anti-impotence pill sold in partnership with ICOS Corp.

(ICOS.O: Quote, Profile, Research), rose 38 percent to $211 million.

Pfizer Inc.'s (PFE.N: Quote, Profile, Research) rival Viagra suffered a sales decline in the quarter, hurt by competition from Lilly's longer-acting product.Lilly reaffirmed its 2006 earnings forecast of $3.10 to $3.20 per share, first delivered last month and excluding special items.

It is in line with the average estimate of $3.13 among analysts polled by Reuters Estimates.The company forecast first-quarter earnings of 73 cents to 75 cents per share, representing growth of 7 percent to ...

UPDATE 3-Lilly profit beats forecasts, helped by lower tax

...The drug's sales fell 15 percent in the United States, but grew 6 percent in overseas markets.

Sales of Strattera, Lilly's treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase the risk of suicidal thoughts among children and adolescents.

Sales of Lilly's diabetes products rose 11 percent to $750 million, helped by the launch of Byetta and higher prices for older treatments.

Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.

Sales of Cialis, the anti-impotence pill sold in partnership with ICOS Corp.

(ICOS.O: Quote, Profile, Research), rose 38 percent to $211 million.

Pfizer Inc.'s (PFE.N: Quote, Profile, Research) rival Viagra suffered a sales decline in the quarter, hurt by competition from Lilly's longer-acting product.

Continued ...

© Reuters 2006.

All Rights Reserved.

1 Careers Reuters journalists are subject to the ...

Eli Lilly Swings To 4Q Profit, Gives '06 Projections

...Sales in the U.S.

fell 15% to $464.2 million, due to lower underlying demand, the company said.

Diabetes-care revenue in the quarter, comprised primarily of Humalog, Humulin, Actos and Byetta, rose 11% to $750.4 million.

U.S.

sales rose 17% to $434.9 million in the quarter.

-Thomas Gryta; Dow Jones Newswires; 201-938-5400; AskNewswires@dowjones.com (END) Dow Jones Newswires January 26, 2006 07:53 ET (12:53 GMT) Copyright (c) 2006 Dow Jones & Company, Inc.

Top .::.

Close Powered by Alpine Interactive All Rights Reserved ...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Medicine   Health and Fitness